TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01356147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy will be given to placebo arm
Study: NCT02516813
Drug: M3814 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 100 mg of M3814 as capsule or tablet orally once daily.
Study: NCT02516813
Drug: M3814 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 200 mg of M3814 as capsule or tablet orally once daily.
Study: NCT02516813
Drug: M3814 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 300 mg of M3814 as capsule or tablet orally once daily.
Study: NCT02516813
Drug: M3814 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 400 mg of M3814 as capsule or tablet orally once daily.
Study: NCT02516813
Drug: M3814 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 100 mg of M3814 as capsule orally once daily.
Study: NCT01772251
Drug: Oshadi Icp
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00391716
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose capsule compounded to mimic gabapentin capsules
Study: NCT02610062
Drug: AGS67E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT03830398
Drug: Deksketoprofen trometamol
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators apply paracetamol during a week in preoperative room 45 min before ECT
Study: NCT03830398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators apply placebo during a week in preoperative room 45 min before ECT
Study: NCT00834574
Drug: OMNICEF® for oral suspension 250 mg/5mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 250 mg/5mL, single dose fasting
Study: NCT01978587
Drug: JTZ-951
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04273646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
Study: NCT00664742
Drug: Fluvastatin XL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin extended release 80 mg
Study: NCT03026777
Drug: intravenous crystalloid fluid, 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00500331
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Drug
Study: NCT03158246
Drug: Generic Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
Study: NCT03158246
Drug: Original Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
Study: NCT03701074
Drug: Ibuprofen and acetaminophen
Normalized name: acetaminophen / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibuprofen given concomitantly with oral acetaminophen
Study: NCT03701074
Drug: Ibuprofen and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibuprofen given concomitantly with oral placebo
Study: NCT01986855
Drug: Placebo 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
Study: NCT02317419
Drug: RO6927005
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
Study: NCT02317419
Drug: RO6927005
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
Study: NCT01986855
Drug: Placebo 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
Study: NCT02221726
Drug: JNJ-35684-AAA-023: Size 1; small patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
Study: NCT02221726
Drug: JNJ-35684-AAA-023: Size 2; large patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
Study: NCT02826681
Drug: Injectafer® (Ferric Carboxymaltose - FCM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Iron
Study: NCT01076699
Drug: 0.075 mg RVX-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group is taking the lowest dose of RVX-100
Study: NCT01076699
Drug: 0.125 mg RVX-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group is taking an average dose of RVX-100
Study: NCT01076699
Drug: 0.250 mg RVX-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group is taking the highest dose of RVX-100
Study: NCT01076699
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group is taking a placebo
Study: NCT02738619
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03745937
Drug: MEDI0382
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
Study: NCT03745937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
Study: NCT03627468
Drug: Sofpironium Bromide Gel, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofpironium Bromide Gel, 5%
Study: NCT03627468
Drug: Sofpironium Bromide Gel, 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofpironium Bromide Gel, 15%
Study: NCT00002670
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00035984
Drug: AC2993
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT00035984
Drug: AC2993
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT00035984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT00035984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT03218553
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
Study: NCT03279328
Drug: Topical Steroid Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
Study: NCT03279328
Drug: Skin Barrier Moisturier
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
Study: NCT02878863
Drug: Paeoniflorin + phosphatidylcholine or silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02878863
Drug: Phosphatidylcholine or silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03032484
Drug: TVB-2640
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
Study: NCT00141011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mL/kg/hr
Study: NCT03982810
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
Study: NCT04503616
Drug: Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
Study: NCT04726527
Drug: Florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
Study: NCT04103814
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
Study: NCT01969409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
Study: NCT02978495
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorrubicin 60 mg/m2 4 cycles each 21 days
Study: NCT02978495
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m2 4 cycles each 21 days
Study: NCT02908217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 Intravenous infusions of placebo every 4 weeks.
Study: NCT01313533
Drug: Polyarginine
Normalized name: Tilarginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein soak treated with polyarginine
Study: NCT03235986
Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
Study: NCT03235986
Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
Study: NCT01871922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT03163667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT03163667
Drug: CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT02082977
Drug: GSK2816126
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
Study: NCT01758120
Drug: prednisone plus cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control
Study: NCT00236041
Drug: ACTIQ®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02871440
Drug: Optive
Normalized name: optive
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03202303
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of 10 mg/kg/day of placebo
Study: NCT01489137
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml.
Study: NCT00319007
Drug: Sulindac (drug)
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00319007
Drug: VSL#3 (probiotic)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01241123
Drug: Sitz-Markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiopaque markers to subjectively follow the return of bowel function
Study: NCT02115529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
Study: NCT02033941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
Study: NCT01275300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00663260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Once Daily, 104 weeks
Study: NCT03708315
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01442610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1tablet once daily for 8 weeks
Study: NCT00330733
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were randomized to 12-week treatment with up to 4 g/day.
Study: NCT00330733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were randomized to 12-week treatment matching the active salsalate arm.
Study: NCT01979185
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00980798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet once daily for 16 weeks
Study: NCT03879798
Drug: DS-3201b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily
Study: NCT01613586
Drug: ASP3652
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01613586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03863574
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Study: NCT04017208
Drug: ASP2713
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04017208
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT03260322
Drug: ASP8374
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT03809351
Drug: [F-18]AV-1451-PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
Study: NCT04278781
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
Study: NCT00666042
Drug: Vigamox - administration in spray form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigamox will be administered in a spray form
Study: NCT00666042
Drug: Vigamox eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigamox eye drops
Study: NCT01374854
Drug: traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: exogenous insulin injection daily
Study: NCT02542215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral spray
Study: NCT02542215
Drug: Standard Care - Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
Study: NCT03503331
Drug: [C-11]PiB-PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
Study: NCT00963287
Drug: bascial prescription plus or minus herbs depend on symptoms
Normalized name: Arctium minus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoction ,two times a day
Study: NCT02402309
Drug: Active topical NS2 1% dermatologic cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02402309
Drug: Vehicle placebo 0.0% NS2 dermatologic cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01225575
Drug: co.don chondrosphere®
Approvals — FDA: no, EMA: no, PMDA: no
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect
Study: NCT02248493
Drug: Placebo (for paracetamol)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02248493
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04265274
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosing 400mg daily
Study: NCT00889330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle without active, one drop in each eye at each of two visits.
Study: NCT00833703
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Study: NCT02063854
Drug: NE-58095 IR Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NE-58095 IR placebo-matching tablets
Study: NCT02063854
Drug: NE-58095 DR Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NE-58095 DR placebo-matching tablets
Study: NCT01053611
Drug: propofol + remifentanil 0 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 0 ng/ml
Study: NCT01053611
Drug: propofol + remifentanil 2 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00751231
Drug: PRT060128
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
Study: NCT01053611
Drug: propofol + remifentanil 4 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01053611
Drug: propofol + remifentanil 6 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01053611
Drug: propofol + remifentanil 0 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01055340
Drug: Oxyntomodulin (OXM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single infusion of OXM 3.0 pmol/kg/min by IV
Study: NCT01055340
Drug: Comparator: Oxyntomodulin (OXM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single infusion of OXM 0.6 pmol/kg/min by IV
Study: NCT01055340
Drug: Comparator: Placebo [ hemaccel-containing saline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Placebo infusion of hemaccel-containing saline by IV
Study: NCT01537432
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT03682367
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of sugar-free Placebo peri- and post-operatively.
Study: NCT04305210
Drug: F-18 PMPBB3
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
Study: NCT00421564
Drug: DBT-Danggui Buxue Tang
Normalized name: Buxus sempervirens leafy twig extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00654602
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02014467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT00900614
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
Study: NCT01511302
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNS60, 2ml, nebulized twice daily.
Study: NCT01511302
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline placebo, 2 ml, nebulized twice daily.
Study: NCT00480532
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
Study: NCT00480532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
Study: NCT00480532
Drug: Doxycycline 100bid x5 days at the time of bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline